Stocks › EBS
Emergent BioSolutions Inc.
EBS·NYSE·
United States·USD
United States·USD$6.95
-0.29 (-4.01%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
EBS
Emergent BioSolutions Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
EBSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of EBS by members of U.S. Congress · 13 on record
Whale Activity
Position changes in EBS reported for 2026-06-30 by 7 tracked institutional filers
- Increased3
- New0
- Held0
- Decreased4
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 4.7M | $39.5M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $18.4M | decreased |
| MILLENNIUM MANAGEMENT LLC | 1.1M | $9.0M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.0M | $8.6M | decreased |
| D. E. Shaw & Co., Inc. | 900.1K | $7.5M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 683.2K | $5.7M | increased |
| TWO SIGMA INVESTMENTS, LP | 488.3K | $4.1M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by EBS insiders, by quarter · Form 4
Recent Insider Transactions
2,961 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Williams Paul AnthonySVP, Products Business | Sale | −3,000 | $6.53 | $20K | Oct 1, 2026 | Form 4 ↗ |
| Williams Paul AnthonySVP, Products Business | Sale | −3,000 | $8.40 | $25K | Jul 1, 2026 | Form 4 ↗ |
| Hartzel WilliamSVP, Bioservices | Tax withholding | −1,741 | $8.00 | $14K | Jun 8, 2026 | Form 4 ↗ |
| Williams Paul AnthonySVP, Products Business | Tax withholding | −694 | $8.00 | $6K | Jun 8, 2026 | Form 4 ↗ |
| Glessner ColeenEVP, Quality & Ethics, and CPL | Tax withholding | −2,018 | $8.00 | $16K | Jun 8, 2026 | Form 4 ↗ |
| LINDAHL RICHARD SEVP, Chief Financial Officer | Tax withholding | −3,964 | $8.00 | $32K | Jun 8, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Sale | −1,057 | $8.97 | $9K | May 1, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Sale | −16.1K | $8.36 | $135K | May 1, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Sale | −954 | $8.96 | $9K | May 1, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Sale | −14.5K | $8.36 | $121K | May 1, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Sale | −980 | $8.94 | $9K | May 1, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Sale | −12.8K | $8.36 | $107K | May 1, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Fowler Neal FranklinDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| White Marvin LDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Harsanyi ZsoltChairman · Director | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Richard RonaldDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Katkin KeithDirector | Sale | −15.5K | $8.28 | $128K | Apr 30, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding EBS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 2.3M | $20.7M | 0.08% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.7M | $14.3M | 0.13% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $13.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.4M | $11.6M | 0.01% | Jun 30, 2026 |
| Schwab Fundamental U.S. Small Company ETF SCHWAB STRATEGIC TRUST | 757.6K | $6.9M | 0.08% | May 31, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 705.6K | $5.1M | 0.03% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 592.8K | $5.0M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund Federated Hermes MDT Series | 630.3K | $4.6M | 0.20% | Jul 31, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 528.6K | $4.4M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 502.4K | $4.2M | 0.03% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list EBS's shares (CUSIP 29089Q105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming emergent biosolutions as client
- CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q2 · DIS, HCR, HOM, BUD$70K
Filing ↗ - THE NICKLES GROUP, LLCEMERGENT BIOSOLUTIONS · 2026 Q2 · BUD, HCR, DEF$40K
Filing ↗ - EMERGENT BIOSOLUTIONS INC.EMERGENT BIOSOLUTIONS INC · 2026 Q2 · BUD, HCR, HOM, DIS$510K
Filing ↗ - CAPITOL COUNSEL LLCEMERGENT BIOSOLUTIONS · 2026 Q2 · HCR$50K
Filing ↗ - CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q1 · HCR, BUD, DIS, HOM$70K
Filing ↗
Government Contracts
Federal awards to emergent biosolutions · USAspending
$320.9MAwarded · 1 contract on record
- Department of Health and Human ServicesBOTULISM ANTITOXIN$320.9M
Sep 30, 2019 · ↗
U.S. Patents
Recent USPTO applications naming Emergent BioSolutions Inc.
No USPTO patent applications found for Emergent BioSolutions Inc..
Annual Financials
From EBS's 10-K filings · XBRL
No annual XBRL figures on record for EBS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in EBS's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 9.01Reg FD disclosureSep 14, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 2.05, 5.02, 7.01, 9.01Results of operations · Exit or disposal costs · Officer / director changeAug 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 29, 2026
EDGAR ↗
About Emergent BioSolutions Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersGAITHERSBURG, MD
IncorporatedDE
SEC CIK0001367644 ↗